Pharma Cold Chain Packaging Review for QA and Procurement

How Quality and Procurement Should Review Pharma Cold Chain Packaging

Quality and procurement teams should evaluate pharma cold chain packaging as a controlled configuration, not as a collection of product claims. The purchase decision must connect the drug requirement and route to an exact shipper, coolant arrangement, payload range, packing method, test basis and change control process.

This guide provides a supplier review framework. It does not replace a company quality system or product specific approval. Its purpose is to help buyers distinguish useful evidence from a box specification, a material data sheet or a duration claim with missing test conditions.

Buy the controlled configuration

A supplier may provide accurate component information without proving that the full packout meets the intended shipment requirement. Procurement should therefore keep five evidence levels separate. Each level answers a different question, and none should be silently treated as the next level.

Write acceptance criteria before the request for quotation

Price comparisons become misleading when suppliers are quoting different system boundaries. One supplier may include coolant and separators, another may quote only the shipper, and a third may base the offer on a different payload or duration. The RFQ should define the decision before asking for a price.

• Product transport limits, relevant sensitivities and the quality owner who approves the requirement.

• Minimum and maximum payloads, usable dimensions, mass, starting condition and orientation limits.

• Route duration, service level, handoffs, seasonal conditions and planned delay allowance.

• Required packout components, conditioning resources, assembly constraints and receiving process.

• Qualification approach, ambient profile rationale, sample expectations, acceptance criteria and report format.

• Shipment volume, reuse model, cleaning or inspection needs, labels, traceability and desired change notification period.

Ask each bidder to state exclusions and assumptions. If the supplier does not have enough route or payload information, the response should remain a design proposal rather than a qualified performance claim.

Read a thermal report as a defined boundary

WHO publishes a dedicated technical supplement on qualification of shipping containers. ISTA also describes Standard 20 for insulated shipping container design and qualification and 7E thermal profiles for parcel shipment testing. ISTA states that 7E does not provide customized lane data or a customized worst case shipping qualification. That distinction matters when a generic profile is used to support a specific route decision.

A report is useful when the buyer can reconstruct what was tested. Review the protocol and approval status, exact component identities, coolant conditioning, loading sequence, payload, headspace, ambient profile, total duration, sensor positions, raw data, deviations and conclusion. Check whether the proposed commercial packout matches that configuration.

Challenge the weak point in the evidence, not just the headline result. A maximum load may resist overcooling but add thermal mass. A minimum load may create more headspace or greater exposure to a cold surface. A long test may still be unrepresentative if the profile, starting conditions or packing steps do not match routine use.

Control the move from samples to production supply

The sample approved during evaluation must remain traceable to the production configuration. Procurement can lower commercial risk by converting the qualified bill of materials into purchase controls instead of relying on a general product family name.

Assign responsibilities before approval

The WHO good storage and distribution practices for medical products place distribution within a quality management framework that includes risk management, qualification, validation, documentation and outsourced activities. A packaging supplier can provide design information and test evidence, but the buyer still needs clear internal ownership for product requirements, route approval and routine release.

• Quality confirms product and market requirements, approves acceptance criteria, reviews deviations and decides whether evidence is adequate.

• Procurement defines the commercial scope, preserves the approved configuration in the contract and manages supplier change obligations.

• Engineering or packaging specialists translate the shipment brief into a design and test plan and evaluate technical differences.

• Operations control conditioning, assembly, labelling, handoff, monitoring and receiving according to the approved instruction.

• The supplier controls its bill of materials and process, provides agreed records and notifies the buyer before relevant changes.

Set change and requalification rules

The ICH Q9 R1 guideline states that quality risk management effort, formality and documentation should be commensurate with risk, and that risk decisions should be reviewed when new knowledge or events may affect them. Use that principle to define review triggers in the quality agreement and internal procedure.

Changes to the shipper, insulation, coolant formulation, fill quantity, separator, closure, payload, logger position, packing site, route, carrier, seasonal profile or work instruction should enter a documented assessment. The result may be no further action, focused verification or partial or full requalification. The quality owner should make that decision from the effect of the change, not from a fixed calendar rule alone.

Use a final supplier evidence checklist

Before commercial approval, confirm that the evidence package answers the following questions:

• Is the product and route requirement approved and traceable to the current specification?

• Does the quotation identify every included component and its controlled revision or specification?

• Does the test report match the proposed payload range, conditioning, layout and intended thermal challenge?

• Are the report limits, deviations and unsupported assumptions visible to the decision makers?

• Can routine operators reproduce the configuration with available equipment and clear instructions?

• Are incoming acceptance, traceability, nonconformance and change notification responsibilities agreed?

• Is the monitoring and excursion process defined without treating the logger as thermal protection?

• Has the organization recorded who approves the configuration and what changes require review?